Gautam Sajeev

Gautam Sajeev

Auto-generated profile, based on publicly available information

Gautam Sajeev

Analysis Group, Inc., Boston, MA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Neurology
Verified
Journal Article
Open access
PDF file
FMFrancesco Muntoni
Francesco Muntoni
JSJames Signorovitch
James Signorovitch
GSGautam Sajeev
Gautam Sajeev
HLHenry Lane
Henry Lane
MJMadeline Jenkins
Madeline Jenkins
AAAnnemieke Aartsma-Rus
Annemieke Aartsma-Rus
Background and Objectives: Clinical trials of genotype-targeted treatments in Duchenne muscular dystrophy (DMD) traditionally compare treated patients to untreated patients with the same DMD genotype class. This avoids confounding of drug efficacy by genotype effects but also shrinks the pool of eligible controls, increasing challenges for trial enrollment in this already rare disease. To evaluate the suitability of genotypically unmatched controls in DMD, we quantified effects of genotype class on 1-year changes in motor function endpoints used in clinical trials. Methods: Over 1,600 patient-years of follow-up (>700 patients) were studied from six real-world/natural history data sources (UZ Leuven, PRO-DMD-01 shared by CureDuchenne, iMDEX, North Star UK, Cincinnati Children’s Hospital Medical Center, and the DMD Italian Group), with genotypes classified as amenable to skipping exons 44, 45, 51 or 53, other skippable, nonsense, and other mutations. Associations between genotype class and 1-year changes in North Star Ambulatory Assessment total score (ΔNSAA) and in 10-meter walk/run velocity (Δ10MWR) were studied in each data source with and without adjustment for baseline prognostic factors. Results: The studied genotype classes accounted for approximately 2% of variation in ΔNSAA outcomes after 12 months, whereas other prognostic factors explained >30% of variation in large data sources. Based on a meta-analysis across all data sources, pooled effect estimates for the studied skip-amenable mutation classes were all small in magnitude (<2 units in ΔNSAA total score in 1-year follow up), smaller than clinically important differences in NSAA, and were precisely estimated with standard errors <1 unit after adjusting for non-genotypic prognostic factors. Discussion: These findings suggest viability of trial designs incorporating genotypically mixed or unmatched controls for up to 12 months in duration for motor function outcomes, which would ease recruitment challenges and reduce numbers of patients assigned to placebos. Such trial designs, including multi-genotype platform trials and hybrid designs, should ensure baseline balance between treatment and control groups for the most important prognostic factors, while accounting for small remaining genotype effects quantified in the present study.

28 February 2023 in Neurology
Verified
Journal Article
Open access
PDF file
NVNienke M. van de Velde
Nienke M. van de Velde
ZKZaïda Koeks
Zaïda Koeks
MSMirko Signorelli
Mirko Signorelli
NVNisha Verwey
Nisha Verwey
MOMaurice Overzier
Maurice Overzier
ENErik H. Niks
Erik H. Niks
Background and Objectives: The slow and variable disease progression of Becker muscular dystrophy (BMD) urges the development of biomarkers to facilitate clinical trials. We explored changes in three muscle-enriched biomarkers in serum of BMD patients over 4 years-time and studied associations with disease severity, disease progression and dystrophin levels in BMD. Methods: We quantitatively measured creatine kinase (CK) using the IFCC reference method, creatine/creatinineratio (Cr/Crn) using liquid chromatography – tandem mass spectrometry (LC-MS/MS) and myostatin with ELISA in serum, and assessed functional performance using North Star Ambulatory Assessment (NSAA), ten-meter run velocity (TMRv), six-minute walking test (6MWT), and Forced Vital Capacity (FVC) in a 4-year prospective natural history study. Dystrophin levels were quantified in the tibialis anterior muscle using capillary Western immunoassay. The correlation between biomarkers, age, functional performance, mean annual change, and prediction of concurrent functional performance were analyzed using linear mixed models. Results: Thirty-four patients with 106 visits were included. Eight patients were non-ambulant at baseline. Cr/Crn and myostatin were highly patient-specific (intraclass correlation coefficient for both=0.960). Cr/Crn was strongly negatively correlated, while myostatin was strongly positively correlated with NSAA, TMRv and 6MWT (Cr/Crn rho=-0.869 to -0.801 and myostatin rho=0.792 to 0.842, all p<0.001). CK showed a negative association with age (p=0.0002) but was not associated with patients’ performance. Cr/Crn and myostatin correlated moderately with average annual change of 6MWT (rho=-0.532 and 0.555, p=0.02). Dystrophin levels did not correlate with the selected biomarkers nor with performance. Cr/Crn, myostatin and age could explain up to 75% of the variance of concurrent functional performance of the NSAA, TMRv and 6MWT. Discussion: Both Cr/Crn and myostatin could potentially serve as monitoring biomarkers in BMD as higher Cr/Crn and lower myostatin were associated with lower motor performance and predictive of concurrent functional performance when combined with age. Future studies are needed to more precisely determine the context of use of these biomarkers.

5 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LMLucia Masarova
Lucia Masarova
TLTom Liu
Tom Liu
MFMirko Fillbrunn
Mirko Fillbrunn
WLWeilong Li
Weilong Li
GSGautam Sajeev
Gautam Sajeev
JSJames Signorovitch
James Signorovitch
Background/Objectives: Red blood cell transfusions for anemia impose high financial and healthcare resource utilization burdens on patients with myelofibrosis (MF). This study estimates projected differences in medical costs and transfusion-related cost and time burdens with momelotinib vs. ruxolitinib or best available therapy (BAT) in Janus kinase (JAK) inhibitor–naive and –experienced patients. Methods: Analyses used 24-week transfusion data from the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials and cost estimates from a study of adult patients with MF using the US IBM MarketScan Commercial database. The analyses were stratified by transfusion status at baseline (transfusion dependent [TD], transfusion independent/requiring [TI/TR]). Subgroup analyses were conducted among patients with anemia (moderate anemia, hemoglobin ≥ 8 to <10 g/dL; moderate-to-severe anemia, hemoglobin < 10 g/dL) and for patients aged ≥65 years. Cost estimates for patients aged ≥65 years were extracted from a study using the Medicare Fee-for-Service database. Results: In JAK inhibitor-naive patients, momelotinib was projected to result in cost and time savings vs. ruxolitinib in both TD and TI/TR patients across all populations evaluated. Projected cost and time savings were also observed with momelotinib vs. BAT in JAK inhibitor-experienced patients across all populations evaluated, primarily in TD patients. Conclusions: These results suggest that momelotinib may provide medical and transfusion-related cost and time burden offsets for both JAK inhibitor-naive and -experienced patients with MF.

23 June 2026 in Neurology
Verified
Journal Article
Open access
CMCraig M. McDonald
Craig M. McDonald
JSJames Signorovitch
James Signorovitch
NGNathalie Marie Goemans
Nathalie Marie Goemans
EMEugenio Mercuri
Eugenio Mercuri
HGHeather Gordish-Dressman
Heather Gordish-Dressman
FMFrancesco Muntoni
Francesco Muntoni
Development of a prognostic score for time to loss of ambulation (LoA) may help guide treatment of patients with Duchenne muscular dystrophy (DMD). Information from clinical data sources was used to create a prognostic score for LoA for use in practice. Data used included 4 natural history databases and 3 clinical trial placebo arms. Inclusion criteria were as follows: (1) 6-minute walk distance ≥75 m; (2) a subsequent visit with an outcome assessment that identified LoA; (3) current corticosteroid use; and (4) available data on prognostic factors. Classification and regression tree models for time to LoA were used to classify patients into 5 risk groups (group 5 = highest risk), prioritizing the easily obtained rise from floor (RFF) and 10-m walk/run (10MWR) times as predictors. The prognostic score was validated in the Cooperative International Neuromuscular Research Group data. Data from 608 boys were analyzed (mean age 9.1 years). Kaplan-Meier curves for time to LoA for each risk group were well separated, describing meaningful differences in time to LoA. Median time to LoA for risk group 1 was not reached during a median of 2.0 years of follow-up. Median times to LoA for risk groups 2-5 were 4.4 (95% CI 4.0-inf), 3.0 (2.1-4.1), 2.0 (1.6-2.1), and 0.9 (0.8-1.6) years, respectively. These risk groups showed concordant times to LoA among 226 patients in the validation data and provided finer separation of patients across different levels of LoA risk than thresholds based on individual functional tests. Patients with DMD were classified into 5 risk groups for LoA using a simple, easy-to-use prognostic score based on RFF and 10MWR thresholds. The prognostic score replicated well in validation data and performed better than previously proposed classifications used in practice. Incorporating the prognostic score for time to LoA into a clinical visit may allow clinicians to counsel patients on trial eligibility, need for mobility devices, home adjustments, financial accommodations, and psychosocial needs. The prognostic score may also be used in trials to inform inclusion criteria and stratification. Study limitations included limited data for prediction of LoA risk beyond 4 years.

12 March 2025 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
TLTom Liu
Tom Liu
MFMirko Fillbrunn
Mirko Fillbrunn
SZShiyuan Zhang
Shiyuan Zhang
JCJingyi Chen
Jingyi Chen
WLWeilong Li
Weilong Li
JSJames Signorovitch
James Signorovitch
Anemia affects many patients with myelofibrosis and is associated with poor prognosis. The Janus kinase inhibitor ruxolitinib is often used in myelofibrosis but may cause or worsen anemia. Using healthcare claims data from the IQVIA PharMetrics Plus database, this retrospective analysis evaluated healthcare resource utilization (HCRU), healthcare costs, and treatment patterns in ruxolitinib-treated patients with myelofibrosis stratified by anemia diagnosis prior to ruxolitinib initiation. Of 11,499 patients diagnosed with myelofibrosis between January 2011 and December 2022, 481 had ≥ 1 ruxolitinib claim on or after the myelofibrosis diagnosis date and were included in this analysis. Mean follow-up was 2.0 years. At baseline, anemic patients (n = 257) were older (mean age, 60.2 vs. 56.8 years; P < 0.001) and had a higher mean Charlson Comorbidity Index (1.0 vs. 0.5; P < 0.001) than nonanemic patients (n = 224). During follow-up, anemic patients exhibited higher median annual all-cause HCRU (inpatient admissions, 0.3 vs. 0.0 [P < 0.001]; outpatient visits, 40.0 vs. 20.0 [P < 0.001]; emergency department visits, 0.4 vs. 0.0 [P < 0.010]) and also had numerically higher median annual all-cause total healthcare costs ($198,491 vs. $170,419; P = 0.549) and medical costs ($44,830 vs. $12,017; P = 0.638) but significantly lower median annual total pharmacy costs ($129,381 vs. $136,686; P < 0.050), compared with nonanemic patients. Ruxolitinib discontinuation rates were higher and median time to discontinuation was approximately 1 year earlier in anemic patients (14.1 vs. 23.8 months; P < 0.010). In conclusion, patients with myelofibrosis and baseline anemia who are treated with ruxolitinib may be an HCRU-intensive population, suggesting a potential need for alternative treatments that reduce their medical resource burden.

2 November 2023 in Blood
Verified
Journal Article
Open access
AKAndrew Kuykendall
Andrew Kuykendall
MFMirko Fillbrunn
Mirko Fillbrunn
TLTom Liu
Tom Liu
AZAdina Zhang
Adina Zhang
RSRyan Simpson
Ryan Simpson
JSJames Signorovitch
James Signorovitch
Disclosures. Kuykendall:BMS: Consultancy, Research Funding; Blueprint: Consultancy, Research Funding, Speakers Bureau; Morphosys: Consultancy, Research Funding;